The shadow of generic rivalry has long loomed above copyright’s iconic drug, Sildenafil, sparking questions about the outlook of connected pharmaceutical portfolios. While initial years saw significant profits, the patent end has opened the door for cheaper copies, possibly lowering earnings and presenting a significant risk for stakeholders purs